Emerging Challenges In Primary Care: 2015
|
|
- Gabriel George
- 5 years ago
- Views:
Transcription
1 Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical Medicine Center for Liver Diseases Medical Director, Liver and GI Transplantation Miami Transplant Institute University of Miami School of Medicine Miami, FL Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Leonard Miller Professor of Medicine Dr. Nasser Ibrahim Al-Rashid Chair Director, Schiff Center for Liver Diseases Director, Hepatology Research Laboratory University of Miami Miller School of Medicine Miami, FL Elliot Wortzel, MD, FACG, FACP Gastroenterology Weston, FL 2 Disclosures Christopher O'Brien, MD, AGAF, FRCMI conducts research for and receives research grants from Gilead, BMS, Abbott (Abbvie), and Janssen. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD is a consultant for Gilead and Merck. He serves on the scientific advisory boards of Bristol Myers Squibb, Gilead, Janssen Pharma, and Acorda; and he serves on the data monitoring boards of Bristol Myers Squibb, Salix, Pfizer, and Arrowhead. Dr. Schiff receives grant/research support from Abbott, Bristol Myers Squibb, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen Pharma, Discovery Life Sciences, Beckman Coulter, Siemens, MedMira, and Conatus. Elliot Wortzel, MD, FACG, FACP has no relationships to disclose. 3 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 1
2 PRE-TEST QUESTIONS 4 Pre-test ARS Question 1 On a scale of 1 to 5, please rate how confident you would be treating a patient with Chronic Hepatitis B: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 5 Case 47-yr-old woman, born in Viet Nam No symptoms Only medical problem: mild hypertension Her husband and 2 sons, aged 20 and 25 yrs, have never been tested for HBV 6 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 2
3 Pre-test ARS Question 2 You decide to screen this patient for Hepatitis B. Which laboratory test confirms the diagnosis of chronic hepatitis B? 1. A positive hepatitis B surface antibody 2. A positive hepatitis B surface antigen and hepatitis B core antibody IgM 3. A positive hepatitis B surface antigen of greater than six months duration 4. A positive hepatitis B core antigen 7 The Screening (and More) Results Hepatitis serologies HBsAg positive, HBcAb positive, HBsAb negative HBeAg negative, anti-hbe positive CBC WBC 4200 cells/mm3, Hb 13 g/dl, platelets 182,000 cells/mm3 Liver Tests AST 12 IU/L, ALT 16 IU/L 8 Pre-test ARS Question 3 Which of the following is not essential for determining further management of patients newly diagnosed with chronic hepatitis B? 1. Ask about family history 2. Order a Fibroscan or an equivalent test 3. Order an abdominal ultrasound 4. Order a liver biopsy 9 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 3
4 Results Fibroscan shows no fibrosis Ultrasound of the abdomen is normal Family history is negative for liver cancer HBV DNA 145 IU/mL 10 Pre-test ARS Question 4 Does the Patient Require Treatment or Only Medical Monitoring? 1. Treatment 2. Medical monitoring only with repeat labs every 6 months and abdominal ultrasound screening 11 Family Member Screening for HBV On screening of the family members for HBV Both sons have been vaccinated and are HBsAb (+) Husband, however, is found to be HBsAg (+), HBcAb (+), HBsAb (-) HBeAg (-) HBV DNA 79,000 IU/mL A Fibroscan shows moderate fibrosis A screening abdominal US is negative 12 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 4
5 Pre-test ARS Question 5 What would be an appropriate treatment for the patient s husband? 1. Tenofovir 300 mg oral daily 2. Ledipasvir 90 mg oral daily 3. Simeprevir 150 mg oral daily 4. Sofosbuvir 400 mg oral daily 13 Learning Objectives Identify patients who should be screened and appropriate testing for those patients Discuss evidence-based strategy for the overall medical management of patients with chronic hepatitis B Determine which patients require medication for chronic hepatitis B and which should be monitored clinically Discuss the medications available for treating chronic hepatitis B and associated resistance issues 14 Geographic Prevalence of Chronic Hepatitis B May Be Impacted by Migration Identify patients who should be and appropriate testing for those patients Discuss evidence-based strategy for the overall medical management of patients with chronic hepatitis B Determine which patients require medication for chronic hepatitis B and which should be monitored clinically Discuss the medications available for treating chronic hepatitis B and associated resistance issues 15 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 5
6 Geographic Prevalence of Chronic Hepatitis B May Be Impacted by Migration ~2 million Asians ~400,000 South Americans ~930, 000 Europeans HBsAg Prevalence 8% - High 2-7% - Intermediate <2% - Low ~350,000 Africans Immigration numbers summed by continent from HBV: A Global Problem HBV is times more infectious than HIV 2 billion people worldwide have been infected with HBV ~ 350 million chronic carriers Leading cause of cirrhosis and hepatocellular carcinoma (HCC) worldwide 30% to 50% of HCC associated with HBV in the absence of cirrhosis Second only to tobacco in causing the most cancer deaths 17 Candidates for HBV Screening Persons born in high and intermediate endemic areas ( 2% prevalence) US-born children of immigrants from high endemic areas ( 8%; only if not vaccinated as infants in the US) Household and sexual contacts of HBV carriers Persons who have injected drugs Persons with multiple sexual partners or history of STDs Men who have sex with men Inmates of correctional facilities Individuals with chronically elevated ALT/AST Individuals infected with HIV or HCV Patients undergoing dialysis Patients undergoing immunosuppressive therapy All pregnant women Infants born to HBV carrier mothers 18 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 6
7 HBV Screening Algorithm Assess HBsAg Positive Negative CHB* Assess anti-hbs Evaluate for treatment Negative (no antibodies) Vaccinate Positive (antibodies present) Immune to HBV *Time from positive HBsAg test to diagnosis of CHB is 6 mos. 19 Outline Identify patients who should be and appropriate testing for those patients Discuss evidence-based strategy for the overall medical management of patients with chronic hepatitis B Determine which patients require medication for chronic hepatitis B and which should be monitored clinically Discuss the medications available for treating chronic hepatitis B and associated resistance issues 20 Natural History of HBV Infection Childhood >95% Immune Tolerance Adulthood <5% HBeAg+ CHB HBeAg- CHB Inac6ve carrier <15-30% of HCC associated with HBV occurs in the absence of cirrhosis or advanced fibrosis HCC 21 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 7
8 Assessment of Hepatic Fibrosis Is liver biopsy necessary for all HBVinfected patients before treatment? Alternatives to biopsy Transient elastography (FibroScan) Non-invasive assays (e.g., FibroTest, APRI, FIB-4) If a subset of patients should be biopsied, who are they? Important to identify patients with cirrhosis in order to define treatment duration 22 Cirrhosis Defined by Morphologic and Functional Changes of the Liver Normal Cirrhosis 23 Indirect Markers of Fibrosis FibroTest/FibroSure Alpha-2 globulin Alpha-2 macroglobulin Gamma globulin Apoliprotein A1 GGT ActiTest Fibrotest +ALT Forns index APRI FIB-4 AST/ALT ratio AST/ALT with plts 24 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 8
9 Fibroscan 25 Fibroscan Propagation Speed Examples Low Speed 4 kpa High Speed 36 kpa 26 Role of Liver Biopsy Needed less frequently Non-invasive tests improving Less essential for decisions regarding timing of treatment Worth considering if Non-invasive tests conflicting and need info to make treatment decision Suspect second disease: e.g. NASH Deferring treatment and concern for advanced disease 27 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 9
10 Medical Management of Cirrhosis Routine assessment for the presence of Fluid retention (ascites) Cognitive impairment (hepatic encephalopathy) Yearly endoscopy (as indicated) Screening for varices Routine HCC screening By ultrasound every 6 months 28 Hepatocellular Carcinoma Screening Screening with Ultrasound recommended at 6 month intervals in all individuals with cirrhosis HCC detected after the onset of symptoms has 0-10% survival at 5 years Early recognition may give a 5-year diseasefree survival of greater than 50% 29 HCC Diagnostic Algorithm Liver nodule < 1 cm > 1 cm Repeat US at 3 months CT or MRI with HCC tumor protocol Growing/changing character Stable Arterial hypervascularity AND venous or delayed phase washout Yes Other contrast Enhanced study (CT or MRI) No Investigate according to size HCC Arterial hypervascularity AND venous or delayed phase washout Biopsy Yes No 30 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 10
11 Outline Identify patients who should be and appropriate testing for those patients Discuss evidence-based strategy for the overall medical management of patients with chronic hepatitis B Determine which patients require medication for chronic hepatitis B and which should be monitored clinically Discuss the medications available for treating chronic hepatitis B and associated resistance issues 31 Course of Chronic HBV Infection is Characterized by Remissions and Relapses 32 HBV Patient Categories HBeAg-positive: Active viral replication Active or inactive liver disease HBeAg-negative: Low-level or no detectable replication Inactive liver disease HBeAg-negative: Active viral replication Active or inactive liver disease 33 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 11
12 Information Needed to Determine HBV Treatment HBeAg status ALT HBV DNA level Degree of liver fibrosis Family history 34 Chronic Hepatitis B Disease Types HBeAg positive Also known as wild type Often, HBV DNA > 20,000 IU/mL HBeAg negative Also known as precore mutant HBV DNA variable 35 New Definition for Elevated ALT Levels Standard reference ranges for ALT vary Men: 4-60 IU/L; women: 6-40 IU/L Men: 0-55 IU/L; women: 0-40 IU/L Both AASLD and US treatment algorithms recommend lower ULN levels for ALT when making treatment-initiation decisions 30 IU/L for men 19 IU/L for women 36 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 12
13 FDA-Approved Therapies First-Line Therapy Peginterferon alfa-2a PEGASYS Roche Laboratories 2005 Entecavir BARACLUDETM Bristol-Myers Squibb 2005 Tenofovir VIREAD Gilead Sciences 2008 Second-Line Therapy Adefovir dipivoxil HEPSERA Gilead Sciences 2002 Telbivudine TYZEKA Idenix and Novartis 2006 Third-Line Therapy Lamivudine EPIVIR-HBV GlaxoSmithKline AASLD Guidelines: Treatment Candidacy for HBeAg-Positive Patients HBsAg positive HBeAg positive ALT < 1 x ULN HBV DNA < 20,000 IU/mL Monitor if not cirrhotic every 6 months ALT 1-2 x ULN HBV DNA > 20,000 IU/mL Treat AASLD Guidelines: Treatment Candidacy for HBeAg-Negative Patients HBsAg positive HBeAg negative ALT < 1 x ULN HBV DNA < 2000 IU/mL q3 mos ALT x 3, then q6-12 mos if ALT still < 1 x ULN ALT ULN HBV DNA 2,000 IU/mL Treat Lok AS, et al. Hepatology. 2009;50: NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 13
14 Algorithm for HBV Management During Pregnancy Previous child HBV (+) No Yes HBV DNA < copies/ml HBV DNA > copies/ml HBV DNA >10 6 copies/ml HBV DNA <10 6 copies/ml Monitor Consider treatment with lamivudine, Tenofovir, or telbivudine at 32 weeks Infant receives HBIG vaccine at birth Prevention of Reactivation During Immunosuppression Prevention is more effective than treatment after HBV-related hepatitis is diagnosed Screen for HBV before start of immunosuppressive therapy Prophylactic antiviral therapy to high + moderate risk patients 41 HBV Treatment in HBV/HIV Coinfected Patients HBV coinfection complicates disease course and management of HIV patients HBV coinfection does not substantially affect the course of HIV infection HIV coinfection significantly alters the course of HBV disease All patients with active HBV infection should be treated with ART containing emtricitabine/tenofovir DF Entecavir may be useful in patients with active replication despite tenofovir or in persons with contraindications to tenofovir in both infections 42 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 14
15 Immunosuppressive Therapies Associated with HBV Reactivation Corticosteroids Anti-tumor necrosis factor Others: methotrexate, molecular target agents Cancer chemotherapy Rituximab anti-cd20 monoclonal antibody 43 Outline Identify patients who should be and appropriate testing for those patients Discuss evidence-based strategy for the overall medical management of patients with chronic hepatitis B Determine which patients require medication for chronic hepatitis B and which should be monitored clinically Discuss the medications available for treating chronic hepatitis B and associated resistance issues 44 Manifestations of Antiviral Resistance 8 Antiviral Treatment HBV DNA (Log 10 IU/mL) ALT (IU/mL) ULN Virologic Breakthrough Genotypic Resistance Virologic Rebound Hepatitis Flare Biochemical Breakthrough Years 45 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 15
16 HBV DNA Testing Indicates chronic hepatitis when still positive 6 mos after diagnosis of acute HBV infection Can differentiate chronic, inactive carrier (< 2000 IU/mL) vs. resolved HBV infection (undetectable) HBV DNA level correlates with disease progression Change in HBV DNA level used to monitor response to therapy Increasing HBV DNA level during antiviral therapy indicates emergence of resistant variants 46 5-Yr Rates of Resistance With Oral Agents in Nucleos(t)ide-Naive Patients Cumulative Resistance Rate (%) Lamivudine Adefovir Telbivudine Entecavir Tenofovir 47 Selection of Entecavir vs Tenofovir: Either Is an Excellent Choice Response at Wk (%) HBeAg seroconversion 2 3 HBsAg loss Entecavir Tenofovir < 1 0 HBsAg loss Parameter Entecavir Tenofovir Log HBV DNA at Wk HBeAg positive HBeAg negative Genotypic resistance, % NA naive 1.2 (Yr 5) 0 (Yr 3) Lamivudine experienced 51 (Yr 5) NR Pregnancy rating Class C Class B AEs None Renal toxicity; BMD HBeAg Positive HBeAg Negative 48 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 16
17 Entecavir or Tenofovir Dosage and Administration Entecavir: oral administration Patients naive to lamivudine therapy: 0.5 mg QD Patients who are refractory/resistant to lamivudine: 1.0 mg QD Dose adjustment needed if egfr < 50 ml/ min Tenofovir: oral administration 300 mg QD Dose adjustment needed if egfr < 50 ml/ min 49 Entecavir or Tenofovir Duration of Therapy Duration, based on clinical endpoints HBeAg positive: Treat until HBV DNA undetectable and HBeAg seroconversion achieved; Continue for 6 mos after anti-hbe appearance Close monitoring for relapse required after treatment discontinuation HBeAg negative: Continue treatment until HBsAg clearance 50 Case Presentation 55 y.o. woman scheduled for treatment of rheumatoid arthritis with Rituximab P.E. positive for arthritic signs consistent with rheumatoid arthritis CBC and CMP WNL Negative viral serologies for hepatitis A and C and HIV Abdominal ultrasound without any significant abnormalities No family history of liver disease No tobacco use; EtOH: 3-4 drinks/wk (wine) 51 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 17
18 *ARS Question What Initial Testing Would You Recommend for This Patient? 1. Schedule a liver biopsy 2. Check her hepatitis B serologies 3. Observe, repeat labs every 6 months 4. Order an ultrasound of the abdomen 52 Testing Results HBsAg (-), HBcAb (+), HBsAb (-) Liver tests are normal CBC is normal 53 Additional Testing Blood fibrosis test shows no fibrosis and the ultrasound of the abdomen is normal HBV DNA 145 IU/mL 54 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 18
19 *ARS Question Does Your Patient Require Treatment or Medical Management? 1. Refer to specialist to be seen 2. Ask the best approach from a friend 3. Start treatment 4. Observe, repeat labs every 6 months 55 *ARS Question Which treatment would you recommend? 1. Sofosbuvir 400 mg oral daily 2. Entecavir 0.5 mg oral daily 3. Simeprevir 150 mg oral daily 4. Ledipasvir 90 mg oral daily 56 POST-TEST QUESTIONS 57 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 19
20 Case 47-yr-old woman, born in Viet Nam No symptoms Only medical problem: mild hypertension Her husband and 2 sons, aged 20 and 25 yrs, have never been tested for HBV 58 Post-test ARS Question 1 You decide to screen this patient for Hepatitis B. Which laboratory test confirms the diagnosis of chronic hepatitis B? 1. A positive hepatitis B surface antibody 2. A positive hepatitis B surface antigen and hepatitis B core antibody IgM 3. A positive hepatitis B surface antigen of greater than six months duration 4. A positive hepatitis B core antigen 59 The Screening (and More) Results Hepatitis serologies HBsAg positive, HBcAb positive, HBsAb negative HBeAg negative, anti-hbe positive CBC WBC 4200 cells/mm3, Hb 13 g/dl, platelets 182,000 cells/mm3 Liver Tests AST 12 IU/L, ALT 16 IU/L 60 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 20
21 Post-test ARS Question 2 Which of the following is not essential for determining further management of patients newly diagnosed with chronic hepatitis B? 1. Ask about family history 2. Order a Fibroscan or an equivalent test 3. Order an abdominal ultrasound 4. Order a liver biopsy 61 Results Fibroscan shows no fibrosis Ultrasound of the abdomen is normal Family history is negative for liver cancer HBV DNA 145 IU/mL 62 Post-test ARS Question 3 Does the Patient Require Treatment or Only Medical Monitoring? 1. Treatment 2. Medical monitoring only with repeat labs every 6 months and abdominal ultrasound screening 63 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 21
22 Family Member Screening for HBV On screening of the family members for HBV Both sons have been vaccinated and are HBsAb (+) Husband, however, is found to be HBsAg (+), HBcAb (+), HBsAb (-) HBeAg (-) HBV DNA 79,000 IU/mL A Fibroscan shows moderate fibrosis A screening abdominal US is negative 64 Post-test ARS Question 4 What would be an appropriate treatment for the patient s husband? 1. Tenofovir 300 mg oral daily 2. Ledipasvir 90 mg oral daily 3. Simeprevir 150 mg oral daily 4. Sofosbuvir 400 mg oral daily 65 Post-test ARS Question 5 On a scale of 1 to 5, please rate how confident you would be treating a patient with Chronic Hepatitis B: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 66 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 22
23 Post-test Question 6 Which of the statements below describes your approach to treating Chronic Hepatitis B? 1. I do not treat patients with Chronic Hepatitis B, nor do I plan to this year. 2. I did not treat patients with Chronic Hepatitis B, but as a result of attending this course I m thinking of doing this now. 3. I do treat patients with Chronic Hepatitis B and this course helped me change my methods. 4. I do treat patients with Chronic Hepatitis B and this course confirmed that I don t need to change my methods. 67 NACE - Emerging Challenges in Primary Care: 2015 Chronic Hepatitis B - 23
Emerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationEmerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New 1 Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor of
More informationEmerging Challenges In Primary Care: 2015
Care Se'ng Emerging Challenges In Primary Care: 2015 Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New Treatments 1 Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationHEPATITIS B: WHO AND WHEN TO TREAT?
HEPATITIS B: WHO AND WHEN TO TREAT? George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department of
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis B Drug: Baraclude (entecavir), Epivir (lamivudine), Hepsera (adefovir), Intron A (interferon alfa- 2b), Pegasys (peginterferon alfa-2a), Tyzeka (telbivudine),
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More information6/9/2015. Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF, FAASLD Director, Schiff Center for Liver Diseases University of Miami
Grant/Research Support: AbbVie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen, Discovery Life Sciences, Beckman Coulter, Inc., Siemens Corporation, MedMira Inc., Conatus Eugene R.
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationHepatitis B Prior Authorization Policy
Hepatitis B Prior Authorization Policy Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review of medical literature,
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationIn Primary Care: 2015
Diagnosis and Management of Chronic HCV and HBV in the Primary Care Setting : Part I - Chronic Hepatitis C: Update on Screening, Diagnosis, Management, and Promising New Treatments Part II - Chronic Hepatitis
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHepatitis B: An Update COPYRIGHT
Hepatitis B: An Update Sanjiv Chopra, M.D. Professor of Medicine Harvard Medical School James Tullis Firm Chief Department of Medicine Beth Israel Deaconess Medical Center A Tale of Serendipity Baruch
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationUpdate on HBV Treatment
Update on HBV Treatment Calvin Q. Pan MD, FAASLD, FACG, MACP Professor of Medicine Division of Gastroenterology and Hepatology Department of Medicine, NYU Langone Health New York University School of Medicine,
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationTreatment of chronic hepatitis delta Case report
Treatment of chronic hepatitis delta Case report George Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National and Kapodistrian University of Athens, Director of Academic Department
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationHepatitis B: Future treatment developments
Hepatitis B: Future treatment developments VIII International Update Workshop in Hepatology Curitiba, 27.08.2016 Christoph Sarrazin St. Josefs-Hospital Wiesbaden and Goethe-University, Frankfurt am Main
More informationMaitines septiembre de 2011 Francisco Jorquera Plaza
Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationA Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update
Accepted Manuscript A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update Paul Martin, MD, Daryl T.-Y. Lau, MD, MSc, MPH, Mindie H. Nguyen, MD,
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationShort title: BENEFIT STUDY, STUDY REPORT (ML25614) Synopsis/Abstract
A Multicenter, prospective, Non-Interventional Study Evaluating Response Parameters during and after Therapy with PEGASYS (Peginterferon alfa-2a 40KD) in Subjects with HBeAg positive or HBeAg negative
More informationACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives
On the Liver Disease Front Lines: Hepatitis A, B and C Prevention and Treatment Kurt Cook, MD, MSc ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family
More informationSerum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads. Hepatology Feb 2013
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Hepatology Feb 2013 Hepatitis B Surface Antigen HBsAg is the glycosylated envelope
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationClinical Case Maria Butí, MD, PhD
Clinical Case Maria Butí, MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital 1 Clinical Case 70 year-old male Smoker, no alcohol intake No risk factors Diabetes Mellitus treated with
More informationDr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1
Dr. John C Rwegasha.FRCP(Lond),MSc, Muhimbili National Hospital Dar es Salaam Tanzania 15/09/2018 1 No disclosures. 15/09/2018 2 Sub-Saharan Africa (SSA) has a high burden of morbidity and mortality resulting
More informationAASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More informationCurrent Issues in Hepatitis B and C
Current Issues in Hepatitis B and C Rena Fox, MD Professor of Clinical Medicine Division of General Internal Medicine May-June 2018 Disclosures: Quality improvement project funded by Gilead Sciences, completed
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More informationHepatitis B in HIV Patients. Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
Hepatitis B in HIV Patients Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center Learning Objectives Identify tests to diagnoses HBV active infection, resolved infection, and need for immunization
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationHepatitis B Reactivation
Hepatitis B Reactivation IOM, December 1 st, 2015 Rohit Loomba, MD, MHSc Professor of Medicine, Division of Gastroenterology and Adjunct Professor, Division of Epidemiology University of California at
More informationBeyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy
: Strategies to Ensure Optimal HBV Screenin g, Diagnosis, and Initial Therapy Sunday, November 1, 2009 Back Bay Ballroom Sheraton Boston Hotel Boston, Massachusetts This program is supported by an educational
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationNovedades en el tratamiento de la hepatitis B: noticias desde la EASL. Maria Buti Hospital Universitario Valle Hebrón Barcelona
Novedades en el tratamiento de la hepatitis B: noticias desde la EASL Maria Buti Hospital Universitario Valle Hebrón Barcelona Milestones in CHB treatment Conventional IFN 1991 Lamivudine (LAM) 1998 Adefovir
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationDon t interfere My first choice is always nucs!
Don t interfere My first choice is always nucs! Robert G Gish MD Professor Consultant Stanford University Medical Director, Hepatitis B Foundation Singapore Viral Hepatitis Meeting 2014 1 Disclosures Dr
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationHepatitis B and Interferon Philippe Sogni Paris-Descartes University, INSERM U-1016 and Hepatology unit, Cochin hospital, Paris; France PHC 2015
Hepatitis B and Interferon Philippe Sogni Paris-Descartes University, INSERM U-1016 and Hepatology unit, Cochin hospital, Paris; France PHC 2015 1 Prof. Philippe SOGNI, M.D., Ph.D. Affiliations Institut
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationFor now, do not stop NUCs PHC R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit
For now, do not stop NUCs PHC 2019 R. PARANÁ Federal University of Bahia, Brazil HUPES-University Hospital Gastro-Hepatology Unit Disclosure PI: Clinical Trials -ABBVIE -INTERCEPT -GILEAD -Novartis -BMS
More informationInitial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH
Initial Evaluation for HCV Therapy Hope McGratty PA-C, MPH Conflict of Interest Disclosure Statement None Who are we talking about today? Treatment naïve Chronic infection This patient seems complicated
More informationDelta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne
Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne Delta hepatitis treatment in 2018 Currently, Peg-IFNα 180 µg/wk is the only effective treatment
More informationHBV/HCV COINFECTIONS IN PATIENTS WITH HIV. Dr Reena Harania MBBS, MRCP, MSc Infectious Disease
HBV/HCV COINFECTIONS IN PATIENTS WITH HIV Dr Reena Harania MBBS, MRCP, MSc Infectious Disease Adults and children estimated to be living with HIV as of end 2005 North America 1.2 million [650 000 1.8 million]
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationHepatitis B: What You Need to Know Hepatitis B 2016
Hepatitis B: What You Need to Know 2016 Tram T. Tran MD Medical Director, Liver Transplant Fellowship Program Director Cedars Sinai Medical Center Associate Professor of Medicine Hepatitis B 2016 New Guidelines
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationModule 1 Introduction of hepatitis
Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationManagement of Hepatitis B & HIV Coinfection: A Clinical Update. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 14, 2008
Management of Hepatitis B & HIV Coinfection: A Clinical Update Douglas G. Fish, MD Albany Medical College Cali, Colombia March 14, 2008 In patients with HIV/HBV co-infection who are HBcoreAb(IgG + IgM)
More informationTerapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri
Terapia dell epatite cronica B: paradigmi attuali e possibili scenari futuri Nicola Coppola Dipartimento di Salute Mentale e Medicina Preventiva Seconda Università di Napoli Main goal of treatment of chronic
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More information